vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $962.7M, roughly 1.6× APTARGROUP, INC.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 4.4%, a 3.3% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 13.5%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $96.9M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 2.6%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
ATR vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $1.5B |
| Net Profit | $74.3M | $66.5M |
| Gross Margin | — | 90.5% |
| Operating Margin | 11.0% | 12.4% |
| Net Margin | 7.7% | 4.4% |
| Revenue YoY | 13.5% | 32.8% |
| Net Profit YoY | -26.4% | 143.8% |
| EPS (diluted) | $1.13 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | $1.5B | ||
| Q3 25 | $961.1M | $1.4B | ||
| Q2 25 | $966.0M | $1.3B | ||
| Q1 25 | $887.3M | $1.1B | ||
| Q4 24 | $848.1M | $1.1B | ||
| Q3 24 | $909.3M | $1.0B | ||
| Q2 24 | $910.1M | $929.2M | ||
| Q1 24 | $915.4M | $751.7M |
| Q4 25 | $74.3M | $66.5M | ||
| Q3 25 | $127.9M | $124.8M | ||
| Q2 25 | $111.7M | $94.3M | ||
| Q1 25 | $78.8M | $1.3M | ||
| Q4 24 | $100.9M | $-151.9M | ||
| Q3 24 | $100.0M | $-121.3M | ||
| Q2 24 | $90.5M | $-120.4M | ||
| Q1 24 | $83.1M | $-251.2M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | — | 87.5% | ||
| Q1 25 | — | 85.2% | ||
| Q4 24 | — | 85.8% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 85.1% | ||
| Q1 24 | — | 83.4% |
| Q4 25 | 11.0% | 12.4% | ||
| Q3 25 | 14.2% | 11.5% | ||
| Q2 25 | 14.9% | 6.7% | ||
| Q1 25 | 12.8% | 1.0% | ||
| Q4 24 | 14.2% | -7.0% | ||
| Q3 24 | 15.2% | -12.0% | ||
| Q2 24 | 13.8% | -11.5% | ||
| Q1 24 | 12.2% | -34.8% |
| Q4 25 | 7.7% | 4.4% | ||
| Q3 25 | 13.3% | 8.8% | ||
| Q2 25 | 11.6% | 7.2% | ||
| Q1 25 | 8.9% | 0.1% | ||
| Q4 24 | 11.9% | -13.5% | ||
| Q3 24 | 11.0% | -12.1% | ||
| Q2 24 | 9.9% | -13.0% | ||
| Q1 24 | 9.1% | -33.4% |
| Q4 25 | $1.13 | $0.05 | ||
| Q3 25 | $1.92 | $0.08 | ||
| Q2 25 | $1.67 | $0.06 | ||
| Q1 25 | $1.17 | $0.00 | ||
| Q4 24 | $1.48 | $-0.10 | ||
| Q3 24 | $1.48 | $-0.09 | ||
| Q2 24 | $1.34 | $-0.09 | ||
| Q1 24 | $1.23 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $4.5B |
| Total DebtLower is stronger | $1.1B | $836.4M |
| Stockholders' EquityBook value | $2.7B | $4.4B |
| Total Assets | $5.3B | $8.2B |
| Debt / EquityLower = less leverage | 0.43× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | $4.5B | ||
| Q3 25 | $264.8M | $4.0B | ||
| Q2 25 | $169.8M | $2.8B | ||
| Q1 25 | $136.8M | $2.5B | ||
| Q4 24 | $226.2M | $2.6B | ||
| Q3 24 | $327.9M | $2.7B | ||
| Q2 24 | $223.9M | $2.6B | ||
| Q1 24 | $201.1M | $2.8B |
| Q4 25 | $1.1B | $836.4M | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
| Q4 25 | $2.7B | $4.4B | ||
| Q3 25 | $2.8B | $4.1B | ||
| Q2 25 | $2.7B | $3.8B | ||
| Q1 25 | $2.5B | $3.5B | ||
| Q4 24 | $2.5B | $3.3B | ||
| Q3 24 | $2.5B | $3.4B | ||
| Q2 24 | $2.4B | $3.4B | ||
| Q1 24 | $2.3B | $3.4B |
| Q4 25 | $5.3B | $8.2B | ||
| Q3 25 | $5.1B | $7.6B | ||
| Q2 25 | $4.9B | $6.3B | ||
| Q1 25 | $4.5B | $5.8B | ||
| Q4 24 | $4.4B | $5.9B | ||
| Q3 24 | $4.6B | $5.8B | ||
| Q2 24 | $4.5B | $5.7B | ||
| Q1 24 | $4.4B | $5.7B |
| Q4 25 | 0.43× | 0.19× | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $417.3M |
| Free Cash FlowOCF − Capex | $96.9M | $379.8M |
| FCF MarginFCF / Revenue | 10.1% | 25.4% |
| Capex IntensityCapex / Revenue | 9.0% | 2.5% |
| Cash ConversionOCF / Net Profit | 2.47× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | $417.3M | ||
| Q3 25 | $177.6M | $402.6M | ||
| Q2 25 | $126.0M | $263.6M | ||
| Q1 25 | $82.7M | $44.1M | ||
| Q4 24 | $178.2M | $75.2M | ||
| Q3 24 | $229.3M | $188.4M | ||
| Q2 24 | $143.6M | $-95.6M | ||
| Q1 24 | $92.3M | $-308.6M |
| Q4 25 | $96.9M | $379.8M | ||
| Q3 25 | $114.3M | $354.5M | ||
| Q2 25 | $62.5M | $219.8M | ||
| Q1 25 | $25.9M | $-12.3M | ||
| Q4 24 | $112.2M | $-17.3M | ||
| Q3 24 | $162.7M | $54.7M | ||
| Q2 24 | $75.4M | $-205.5M | ||
| Q1 24 | $16.7M | $-465.1M |
| Q4 25 | 10.1% | 25.4% | ||
| Q3 25 | 11.9% | 25.1% | ||
| Q2 25 | 6.5% | 16.7% | ||
| Q1 25 | 2.9% | -1.1% | ||
| Q4 24 | 13.2% | -1.5% | ||
| Q3 24 | 17.9% | 5.5% | ||
| Q2 24 | 8.3% | -22.1% | ||
| Q1 24 | 1.8% | -61.9% |
| Q4 25 | 9.0% | 2.5% | ||
| Q3 25 | 6.6% | 3.4% | ||
| Q2 25 | 6.6% | 3.3% | ||
| Q1 25 | 6.4% | 5.0% | ||
| Q4 24 | 7.8% | 8.2% | ||
| Q3 24 | 7.3% | 13.3% | ||
| Q2 24 | 7.5% | 11.8% | ||
| Q1 24 | 8.3% | 20.8% |
| Q4 25 | 2.47× | 6.28× | ||
| Q3 25 | 1.39× | 3.22× | ||
| Q2 25 | 1.13× | 2.79× | ||
| Q1 25 | 1.05× | 34.71× | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | 1.59× | — | ||
| Q1 24 | 1.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
ONC
Segment breakdown not available.
